This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O’Rourke, M. F. Search for Related Content PubMed PubMed Citation Articles by O’Rourke, M. F. Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2238.)
© 2005 American Heart Association, Inc.

Editorials

Beyond Blood Pressure

Subtle Effects of Drug Classes

Michael F. O’Rourke

From the University of New South Wales/St. Vincent’s Clinic/ VCCRI, Sydney, Australia.

Correspondence to M. O’Rourke, Suite 810, St. Vincent’s Clinic, 438 Victoria St, Darlinghurst, NSW 2010, Australia. E-mail M.ORourke@unsw.edu.au

An extract of the first 250 words of the full text is provided, because this article has no abstract.

In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Schillaci et al¹ raise an interesting possibility—that a drug class (protease inhibitors) can have subtle arterial ill effects, which are not apparent from conventional blood pressure recordings. The authors provide evidence of aortic stiffening (measured as carotid–femoral pulse wave velocity [PWV]), increase in wave reflection from peripheral vessels (measured as aortic augmentation index [AIx]), and impairment of left ventricular subendocardial supply/demand ratio (measured as Buckberg index). Studies to date on arterial stiffening and its implications have concentrated on how age, gender, body height, exercise, lifestyle, and disease affects these properties, and how arterial properties, when deranged by disease, can be improved by drug therapy.² Such adverse arterial hemodynamic changes with drugs have not been sought before. Before approval of a new drug, government regulatory bodies have required only measurements of cuff brachial systolic and diastolic pressures and assurance that these were not significantly altered. The question arises from the study of Schillaci—is this enough? Is it possible that drug classes may have adverse long-term effects that are not exposed by conventional cuff measurements? The question is relevant to the present concerns on long-term ill effects of COX 2 inhibitors (coxibs), with rofecoxib withdrawn from the market and the subject of legal action in US courts.³

See page 2381

The potential importance of the findings of Schillaci et al on protease inhibitors is unquestioned. These drugs have revolutionised the treatment of AIDS and find routine use in persons who are seropositive . . . [Full Text of this Article]

Related Article:

Impact of Treatment With Protease Inhibitors on Aortic Stiffness in Adult Patients With Human Immunodeficiency Virus Infection

Giuseppe Schillaci, Giuseppe V.L. De Socio, Matteo Pirro, Gianluca Savarese, Massimo R. Mannarino, Franco Baldelli, Giuliano Stagni, and Elmo Mannarino
Arterioscler Thromb Vasc Biol 2005 25: 2381-2385. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				M. F. O'Rourke and J. B. Seward Central Arterial Pressure and Arterial Pressure Pulse: New Views Entering the Second Century After Korotkov Mayo Clin. Proc., August 1, 2006; 81(8): 1057 - 1068. [Abstract] [Full Text] [PDF]